drugset / Trial / NCT03400306
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
RandomizedCrossoverOpen-labelTreatment
Summary
This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.
Timeline
- Start
- 2021-11-15
- Primary completion
- 2021-11-16
- Completion
- 2021-11-16
Outcome
Outcome not reported
Stopped (Business): “Strategic considerations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Veliparib | Small molecule | 400 mg | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |